115 related articles for article (PubMed ID: 9377590)
1. Preclamol and parkinsonian fluctuations.
Pirtosek Z; Merello M; Carlsson A; Stern G
Clin Neuropharmacol; 1993 Dec; 16(6):550-4. PubMed ID: 9377590
[TBL] [Abstract][Full Text] [Related]
2. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Metman LV; Sethy VH; Roberts JR; Bravi D; Hoff JI; Mouradian MM; Chase TN
Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854
[TBL] [Abstract][Full Text] [Related]
3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
[No Abstract] [Full Text] [Related]
5. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
Williams M; Wright S; Lloyd GK
Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
[No Abstract] [Full Text] [Related]
6. [Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine].
Krankenpfl J; 2005; 43(7-10):241. PubMed ID: 16515311
[No Abstract] [Full Text] [Related]
7. [New types of dopaminergic treatment. The Danish Society of Movement Disorders].
Karlsborg M; Regeur L
Ugeskr Laeger; 2006 Mar; 168(12):1209. PubMed ID: 16571300
[No Abstract] [Full Text] [Related]
8. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
Albani C; Zangger I; Fischer G
Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
[TBL] [Abstract][Full Text] [Related]
9. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
10. Addiction to apomorphine: a clinical case-centred discussion.
Téllez C; Bustamante ML; Toro P; Venegas P
Addiction; 2006 Nov; 101(11):1662-5. PubMed ID: 17034447
[TBL] [Abstract][Full Text] [Related]
11. Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease.
Pirtosek Z; Merello M; Carlsson A; Stern G
Adv Neurol; 1996; 69():535-40. PubMed ID: 8615177
[No Abstract] [Full Text] [Related]
12. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
Gulwadi AG; Korpinen CD; Mailman RB; Nichols DE; Sit SY; Taber MT
J Pharmacol Exp Ther; 2001 Feb; 296(2):338-44. PubMed ID: 11160615
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
14. Apomorphine-induced penile erections in Parkinson's disease.
O'Sullivan JD; Hughes AJ
Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
[TBL] [Abstract][Full Text] [Related]
15. Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography.
Vasdev N; Natesan S; Galineau L; Garcia A; Stableford WT; McCormick P; Seeman P; Houle S; Wilson AA
Synapse; 2006 Sep; 60(4):314-8. PubMed ID: 16786538
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine in dopaminergic therapy.
Subramony JA
Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
[TBL] [Abstract][Full Text] [Related]
18. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
[TBL] [Abstract][Full Text] [Related]
19. Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys.
Luquin MR; Guillén J; Legarda I; Cruz Rodriguez M; Del Rio L; Dominguez J; Martínez-Lage JM
Adv Neurol; 1996; 69():239-44. PubMed ID: 8615134
[No Abstract] [Full Text] [Related]
20. Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips.
d'Emmanuele di Villa Bianca R; Sorrentino R; Roviezzo F; Imbimbo C; Palmieri A; De Dominicis G; Montorsi F; Cirino G; Mirone V
Int J Impot Res; 2005; 17(2):127-33. PubMed ID: 15549138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
